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background:  Beta-blocker therapy has been established as an essential drug to reduce mortality and re-infarction in acute myocardial infarction 
(AMI) with impaired left ventricular dysfunction. However, in primary percutaneous coronary intervention (PCI) era, there has been no report 
demonstrating the benefits of beta-blocker after primary PCI in AMI without heart failure (HF).
methods: The ALPS-AMI Study was a multi-center study enrolling 508 AMI patients. We prospectively tracked cardiovascular events for 2 years in 
423 patients (mean age 68.5±11.5 years-old and 19% female) without HF on admission from this cohort. To assess the effect of beta-blocker, we 
divided them into two group depended on beta-blocker. The primary endpoint was cardiovascular death.
results: Clinical follow-up was completed in 402/423 patients (95.0%). There were 18 all-cause death (4%), 11 cardiovascular death (3%), 9 HF 
(2%) and 6 stroke (1%). There was no incidence of re-infarction. In Kaplan-Meier analysis, there were no statistical difference between the patients 
with and without beta-blocker in cardiovascular death, HF, stroke and composite endpoints of them (2% vs. 4%, p=0.087, 2% vs. 2%, p=0.768, 2% 
vs. 2%, p=0.993 and 5% vs. 7%, p=0.602, respectively).
Conclusions: This study demonstrated no clinical benefit of beta-blocker after primary PCI in AMI without HF. Extended follow-up is warranted to 
assess the long-term benefit of beta-blocker after primary PCI.
